Genentech Company Description
"The few, the proud, the profitable" could be Genentech's motto. One of the world's most successful biotechs (in an industry full of money-losers), the firm has three billion-dollar blockbusters: Rituxan, which fights non-Hodgkin's lymphoma; Avastin, a treatment for colorectal and non-small cell lung cancers; and Herceptin for breast cancer. Lung cancer drug Tarceva rounds out the company's oncology portfolio. Genentech's other marketed drugs include cardiovascular therapies Activase and TNKase, human growth hormone Nutropin, cystic fibrosis drug Pulmozyme, and asthma drug Xolair. Products are sold through direct marketing and large drug distributors including AmerisourceBergen. Roche owns 56% of the firm.
View the Comprehensive Company Description for Genentech
The Company Description provides a historical perspective of Genentech's organization from inception to current status.
Produced by Hoover's in-house editorial team, the Company Description tracks ownership transitions, company progress via mergers and acquisitions, major growth milestones, and strategic initiatives, to provide a holistic view of Genentech's evolution in the marketplace.
